← All organizations
PharmaEssentia Corp.
For profitContributed to NME
Also known as: PharmaEssentia | PharmaEssentia Corp. | PharmaEssentia Corporation | PharmaEssentia Corporation (Co-Sponsor for USA) | PharmaEssentia (Co-Sponsor for USA) | PharmaEssentia Japan K.K. | PharmaEssentia USA Corporation
Highest phase reached
Phase 4
First clinical trial
Nov 7, 2009First marketed drug
Nov 12, 2021First NDA
Nov 12, 2021Last known activity
Aug 27, 2025
Timeline
2000s
- Jun 1, 2003
PharmaEssentia Corp.— Founded
2020s
- Nov 12, 2021
ropeginterferon alfa-2b-njft— NDA Organization
- Nov 12, 2021
ropeginterferon alfa-2b-njft— NDA Secondary Org
Drugs by trial phase (14 distinct, 29 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
Marketed drugs (1)
Recent trials (39)
- NCT07047885CollaboratorPhase 1Aug 27, 2025
- NCT07053904Lead sponsorPhase 1Apr 21, 2025
- NCT06290765Lead sponsorPhase 4Jan 1, 2025
- NCT06468033Lead sponsorPhase 3Dec 31, 2024
- NCT06698861Lead sponsorPhase 1Aug 19, 2024
- NCT06002490Lead sponsorPhase 3Oct 17, 2023
- NCT05481151Lead sponsorPhase 3Oct 26, 2022
- NCT05481151Study directorPhase 3Oct 26, 2022
- NCT05482971Study directorPhase 2Sep 29, 2022
- NCT05482971Lead sponsorPhase 2Sep 29, 2022
- NCT05467553CollaboratorPhase 2Aug 31, 2022
- NCT05231044Lead sponsorPhase 3Dec 21, 2021
- NCT05231044CollaboratorPhase 3Dec 21, 2021
- NCT05245578Lead sponsorPhase 1Nov 16, 2021
- NCT05245578CollaboratorPhase 1Nov 16, 2021
Details
- Founded
- Burlington, MA, US Jun 1, 2003
- First NDA
- Nov 12, 2021
- Last known activity
- Aug 27, 2025
Designations held
- Orphan drug